Small study checks early bacteria-killing power of common MAC drug
NCT ID NCT04287049
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This pilot study looked at how well the antibiotic azithromycin kills Mycobacterium avium complex (MAC) bacteria in the lungs during the first 14 days of treatment. Ten adults with MAC lung disease took azithromycin daily, and researchers measured bacterial levels in their sputum. The goal was to understand early drug activity, not to test a cure or new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM AVIUM COMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.